Get started
Author

Liam B Oakley

Observed names: L. B. Oakley, Liam Oakley
Observed institution: Dana-Farber Cancer Institute
ORCID: 0009-0004-5090-8778
Observed ORCID: 0009-0004-5090-8778
OpenAlex ID: A5113301093
Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2024 · Glenn J. Hanna, L. B. Oakley, et al. · Clinical Cancer Research · 10
PDF
Duvelisib with docetaxel for patients with anti-PD-1 refractory, recurrent, or metastatic head and neck squamous cell carcinoma.
2024 · Glenn J. Hanna, Liam B Oakley, et al. · Journal of Clinical Oncology · 2
Phase II trial of regorafenib in metastatic medullary thyroid carcinoma (MTC) and radioactive iodine refractory differentiated thyroid carcinoma (RAIR DTC).
2024 · Kartik Sehgal, Ruichao Shi, et al. · Journal of Clinical Oncology · 1
Supplemental Appendix 1 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Glenn J. Hanna, L. B. Oakley, et al.
Data from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Glenn J. Hanna, L. B. Oakley, et al.
Supplemental Table 1 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Glenn J. Hanna, L. B. Oakley, et al.
Supplemental Table 7 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Glenn J. Hanna, L. B. Oakley, et al.
Supplemental Table 5 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Glenn J. Hanna, L. B. Oakley, et al.
Supplemental Table 4 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Glenn J. Hanna, L. B. Oakley, et al.
Supplemental Table 6 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Glenn J. Hanna, L. B. Oakley, et al.
Supplemental Table 3 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Glenn J. Hanna, L. B. Oakley, et al.
Supplemental Table 2 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Glenn J. Hanna, L. B. Oakley, et al.
Supplemental Table 4 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Glenn J. Hanna, L. B. Oakley, et al.
Supplemental Table 5 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Glenn J. Hanna, L. B. Oakley, et al.
Supplemental Appendix 1 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Glenn J. Hanna, L. B. Oakley, et al.
Supplemental Table 7 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Glenn J. Hanna, L. B. Oakley, et al.
Supplemental Table 1 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Glenn J. Hanna, L. B. Oakley, et al.
Supplemental Table 6 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Glenn J. Hanna, L. B. Oakley, et al.
Supplemental Table 2 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Glenn J. Hanna, L. B. Oakley, et al.
Supplemental Table 3 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Glenn J. Hanna, L. B. Oakley, et al.
453 KSQ-004EX: a SOCS1/Regnase-1 dual-edited eTIL therapy demonstrating enhanced anti-tumor activity
2024 · Gustavo Martinez, Alexander Smashnov, et al. · Journal for ImmunoTherapy of Cancer
Works count: 21
Citation count: 13
H-index: 2
I10-index: 1
Year
Topic
Type